Pacira BioSciences (NASDAQ:PCRX) Hits New 1-Year Low at $25.74

Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) reached a new 52-week low during mid-day trading on Monday . The company traded as low as $25.74 and last traded at $25.76, with a volume of 63285 shares changing hands. The stock had previously closed at $26.25.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on PCRX shares. Needham & Company LLC reiterated a "buy" rating and issued a $45.00 price target on shares of Pacira BioSciences in a research note on Tuesday, April 9th. HC Wainwright restated a "buy" rating and issued a $57.00 price target on shares of Pacira BioSciences in a research note on Monday, March 4th. JPMorgan Chase & Co. started coverage on Pacira BioSciences in a report on Thursday, March 7th. They set an "overweight" rating and a $45.00 price target for the company. TheStreet raised Pacira BioSciences from a "d+" rating to a "c" rating in a research report on Thursday, February 29th. Finally, Royal Bank of Canada dropped their price target on shares of Pacira BioSciences from $53.00 to $45.00 and set an "outperform" rating on the stock in a research note on Friday, March 1st. Eleven investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Pacira BioSciences presently has an average rating of "Buy" and a consensus target price of $49.50.

Pacira BioSciences Price Performance

The company has a debt-to-equity ratio of 0.59, a quick ratio of 4.17 and a current ratio of 5.24. The company has a market capitalization of $1.21 billion, a PE ratio of 32.41 and a beta of 0.76. The company's 50-day simple moving average is $29.04 and its 200-day simple moving average is $29.78.

Pacira BioSciences (NASDAQ:PCRX - Get Free Report) last released its quarterly earnings results on Thursday, February 29th. The company reported $0.71 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $0.71. Pacira BioSciences had a return on equity of 12.81% and a net margin of 6.22%. The firm had revenue of $181.24 million for the quarter, compared to analyst estimates of $180.60 million. As a group, sell-side analysts anticipate that Pacira BioSciences, Inc. will post 2.18 earnings per share for the current year.

Insiders Place Their Bets

In other Pacira BioSciences news, Director Gary W. Pace sold 90,000 shares of the stock in a transaction on Friday, March 8th. The stock was sold at an average price of $30.60, for a total value of $2,754,000.00. Following the completion of the transaction, the director now owns 22,127 shares in the company, valued at $677,086.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Gary W. Pace sold 1,066 shares of Pacira BioSciences stock in a transaction on Wednesday, March 6th. The stock was sold at an average price of $29.67, for a total transaction of $31,628.22. Following the completion of the transaction, the director now directly owns 140,384 shares of the company's stock, valued at $4,165,193.28. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gary W. Pace sold 90,000 shares of the company's stock in a transaction on Friday, March 8th. The shares were sold at an average price of $30.60, for a total value of $2,754,000.00. Following the completion of the sale, the director now directly owns 22,127 shares in the company, valued at approximately $677,086.20. The disclosure for this sale can be found here. 6.60% of the stock is owned by insiders.

Institutional Investors Weigh In On Pacira BioSciences

Large investors have recently added to or reduced their stakes in the business. Legato Capital Management LLC purchased a new position in Pacira BioSciences in the 3rd quarter valued at about $295,000. SG Americas Securities LLC lifted its stake in shares of Pacira BioSciences by 37.7% during the third quarter. SG Americas Securities LLC now owns 21,843 shares of the company's stock valued at $670,000 after buying an additional 5,979 shares during the period. Everence Capital Management Inc. boosted its position in Pacira BioSciences by 46.3% during the third quarter. Everence Capital Management Inc. now owns 8,940 shares of the company's stock worth $274,000 after acquiring an additional 2,830 shares during the last quarter. Exchange Traded Concepts LLC purchased a new stake in Pacira BioSciences in the 3rd quarter worth approximately $466,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Pacira BioSciences by 33.8% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,946 shares of the company's stock worth $336,000 after purchasing an additional 2,764 shares during the period. 99.73% of the stock is owned by institutional investors and hedge funds.

Pacira BioSciences Company Profile

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.